Roche’s Valcyte Patent: Flawed Obviousness Analysis?
An anonymous commentator wrote in to suggest that the Indian patent office was wrong in its “obviousness” analysis of Roche’s claim covering Valgancyclovir. I had blogged on this case earlier, suggesting that the Indian patent office seems to have endorsed an “obvious to try” test. And that its decision appears to be a sound and logically coherent one (at least on “obviousness”). Our commentator however takes issue with the decision. The commentators’ analysis turns on a critical fact: that a […]
Roche’s Valcyte Patent: Flawed Obviousness Analysis? Read More »


